Brausa, Adam R. <ABrausa@mofo.com>
`Friday, May 3, 2024 2:40 PM
`Laura Fairneny; Hillier, Drew Alan
`QE - Samsung Bioepis; MYL_REG_IPR@rmmslegal.com; Lora Green; Franklin Chu;
`rcerwinski@geminilaw.com; azalcenstein@geminilaw.com; bmorris@geminilaw.com;
`Durie, Daralyn J.; Davis, Kira A; Weires, Rebecca; Regeneron-MoFo-IPR; Wilk, Matthew
`M.; Cobb, Jeremy; Caine, David A.
`RE: IPR2023-00884: Additional Discovery
`
`Follow up
`Flagged
`
`[EXTERNAL EMAIL from abrausa@mofo.com]
`
`From:
`Sent:
`To:
`Cc:
`
`Subject:
`
`Follow Up Flag:
`Flag Status:
`
`To
`help
`prot
`ect
`your
`priva
`cy,
`
`Laura,
`
`Drew is out with some appointments today, and I’m not sure of his availability, so I can respond. Regeneron is fully
`cooperating and is attempting to actually meet and confer. Samsung on the other hand refuses to provide any specific
`justification for its untimely requests for additional discovery. To date, Samsung has not offered any explanation for
`why its request for numerous trial exhibits is “necessary in the interest of justice” as articulated in Garmin Int'l, Inc. v.
`Cuozzo Speed Tech. L.L.C., IPR2012-00001, Paper 26 (P.T.A.B. Mar. 5, 2013), or why it waited so long to seek this
`additional discovery. As such, Regeneron opposes Samsung’s proposed motion for leave to seek additional
`discovery. We can be available on Tuesday or Thursday of next week from 11-5 ET for a call with the Board. Thanks.
`
`Regards,
`Adam
`
`Adam Brausa
`abrausa@mofo.com
`T: +1 (415) 268-6053
`M: +1 (773) 426-9492
`
`Morrison Foerster
`425 Market St.
`San Francisco, CA 94105
`
`mofo.com | LinkedIn | Twitter
`
`From: Laura Fairneny <laurafairneny@quinnemanuel.com>
`Sent: Friday, May 3, 2024 12:30 PM
`To: Hillier, Drew Alan <DHillier@mofo.com>
`Cc: QE - Samsung Bioepis <qe-samsungbioepis@quinnemanuel.com>; MYL_REG_IPR@rmmslegal.com; Lora Green
`
`1
`
`Samsung Bioepis Exhibit 1070
`Page 1
`
`

`

`<lgreen@geminilaw.com>; Franklin Chu <fchu@geminilaw.com>; rcerwinski@geminilaw.com;
`azalcenstein@geminilaw.com; bmorris@geminilaw.com; Brausa, Adam R. <ABrausa@mofo.com>; Durie, Daralyn J.
`<DDurie@mofo.com>; Davis, Kira A <KiraDavis@mofo.com>; Weires, Rebecca <RWeires@mofo.com>; Regeneron-
`MoFo-IPR <Regeneron-MoFo-IPR@mofo.com>; Wilk, Matthew M. <Matthew.Wilk@arnoldporter.com>; Cobb, Jeremy
`<Jeremy.Cobb@arnoldporter.com>; Caine, David A. <David.Caine@arnoldporter.com>
`Subject: RE: IPR2023-00884: Additional Discovery
`
`External Email
`
`Counsel,
`
`We have tried to resolve this request for additional discovery without requiring the Board’s involvement, but Regeneron
`is not cooperating in that process. We plan to email the Board to request leave to file a motion for the additional
`discovery and raise Regeneron’s refusal to meet and confer in a timely manner.
`
`Please send us times you are available for a conference call with the Board next week.
`
`Regards,
`Laura
`
`From: Laura Fairneny
`Sent: Friday, May 3, 2024 12:16 PM
`To: Hillier, Drew Alan <DHillier@mofo.com>
`Cc: QE - Samsung Bioepis <qe-samsungbioepis@quinnemanuel.com>; MYL_REG_IPR@rmmslegal.com; Lora Green
`<lgreen@geminilaw.com>; Franklin Chu <fchu@geminilaw.com>; rcerwinski@geminilaw.com;
`azalcenstein@geminilaw.com; bmorris@geminilaw.com; Brausa, Adam R. <ABrausa@mofo.com>; Durie, Daralyn J.
`<DDurie@mofo.com>; Davis, Kira A <KiraDavis@mofo.com>; Weires, Rebecca <RWeires@mofo.com>; Regeneron-
`MoFo-IPR <Regeneron-MoFo-IPR@mofo.com>; Wilk, Matthew M. <Matthew.Wilk@arnoldporter.com>; Cobb, Jeremy
`<Jeremy.Cobb@arnoldporter.com>; Caine, David A. <David.Caine@arnoldporter.com>
`Subject: RE: IPR2023-00884: Additional Discovery
`
`Drew,
`
`We cannot wait that long. I’m happy to discuss with another member of your team at the proposed times today, talk to
`you on Saturday, or get Regeneron’s position by email. This cannot be drawn out by Regeneron any longer.
`
`Regards,
`Laura
`
`From: Hillier, Drew Alan <DHillier@mofo.com>
`Sent: Friday, May 3, 2024 12:13 PM
`To: Laura Fairneny <laurafairneny@quinnemanuel.com>
`Cc: QE - Samsung Bioepis <qe-samsungbioepis@quinnemanuel.com>; MYL_REG_IPR@rmmslegal.com; Lora Green
`<lgreen@geminilaw.com>; Franklin Chu <fchu@geminilaw.com>; rcerwinski@geminilaw.com;
`azalcenstein@geminilaw.com; bmorris@geminilaw.com; Brausa, Adam R. <ABrausa@mofo.com>; Durie, Daralyn J.
`<DDurie@mofo.com>; Davis, Kira A <KiraDavis@mofo.com>; Weires, Rebecca <RWeires@mofo.com>; Regeneron-
`MoFo-IPR <Regeneron-MoFo-IPR@mofo.com>; Wilk, Matthew M. <Matthew.Wilk@arnoldporter.com>; Cobb, Jeremy
`<Jeremy.Cobb@arnoldporter.com>; Caine, David A. <David.Caine@arnoldporter.com>
`Subject: RE: IPR2023-00884: Additional Discovery
`
`2
`
`Samsung Bioepis Exhibit 1070
`Page 2
`
`

`

`[EXTERNAL EMAIL from dhillier@mofo.com]
`
`Laura,
`
`I am not available today. Are you available at 10:00 a.m. on Tuesday? We can use the dial-in that I circulated below.
`
`Thank you,
`
`Drew
`
`Drew Alan Hillier
`Associate
`DHillier@mofo.com
`T +1 (858) 314-7711
`M +1 (858) 252-5131
`
`From: Laura Fairneny <laurafairneny@quinnemanuel.com>
`Sent: Friday, May 3, 2024 8:04 AM
`To: Hillier, Drew Alan <DHillier@mofo.com>
`Cc: QE - Samsung Bioepis <qe-samsungbioepis@quinnemanuel.com>; MYL_REG_IPR@rmmslegal.com; Lora Green
`<lgreen@geminilaw.com>; Franklin Chu <fchu@geminilaw.com>; rcerwinski@geminilaw.com;
`azalcenstein@geminilaw.com; bmorris@geminilaw.com; Brausa, Adam R. <ABrausa@mofo.com>; Durie, Daralyn J.
`<DDurie@mofo.com>; Davis, Kira A <KiraDavis@mofo.com>; Weires, Rebecca <RWeires@mofo.com>; Regeneron-
`MoFo-IPR <Regeneron-MoFo-IPR@mofo.com>; Wilk, Matthew M. <Matthew.Wilk@arnoldporter.com>; Cobb, Jeremy
`<Jeremy.Cobb@arnoldporter.com>; Caine, David A. <David.Caine@arnoldporter.com>
`Subject: RE: IPR2023-00884: Additional Discovery
`
`External Email
`
`Drew,
`
`Please let me know your availability today.
`
`Regards,
`Laura
`
`From: Laura Fairneny
`Sent: Thursday, May 2, 2024 5:19 PM
`To: Hillier, Drew Alan <DHillier@mofo.com>
`Cc: QE - Samsung Bioepis <qe-samsungbioepis@quinnemanuel.com>; MYL_REG_IPR@rmmslegal.com; Lora Green
`<lgreen@geminilaw.com>; Franklin Chu <fchu@geminilaw.com>; rcerwinski@geminilaw.com;
`azalcenstein@geminilaw.com; bmorris@geminilaw.com; Brausa, Adam R. <ABrausa@mofo.com>; Durie, Daralyn J.
`<DDurie@mofo.com>; Davis, Kira A <KiraDavis@mofo.com>; Weires, Rebecca <RWeires@mofo.com>; Regeneron-
`
`3
`
`Samsung Bioepis Exhibit 1070
`Page 3
`
`

`

`MoFo-IPR <Regeneron-MoFo-IPR@mofo.com>; Wilk, Matthew M. <Matthew.Wilk@arnoldporter.com>; Cobb, Jeremy
`<Jeremy.Cobb@arnoldporter.com>; Caine, David A. <David.Caine@arnoldporter.com>
`Subject: Re: IPR2023-00884: Additional Discovery
`
`Drew,
`
`I can also make myself available tomorrow from 2:30-5pm ET.
`
`Regards,
`Laura
`
`On May 2, 2024, at 5:08 PM, Hillier, Drew Alan <DHillier@mofo.com> wrote:
`
`[EXTERNAL EMAIL from dhillier@mofo.com]
`
`Laura,
`
`We do think it makes sense to wait until we hear from Mylan on whether Mylan objects. I am not
`available to speak tomorrow before 9:30 a.m. PT. If 10:00 a.m. PT does not work for you on Tuesday,
`please propose some additional times.
`
`Thank you,
`
`Drew
`
`Drew Alan Hillier
`Associate
`DHillier@mofo.com
`T +1 (858) 314-7711
`M +1 (858) 252-5131
`
`<image001.png>
`
`From: Laura Fairneny <laurafairneny@quinnemanuel.com>
`Sent: Thursday, May 2, 2024 12:27 PM
`To: Hillier, Drew Alan <DHillier@mofo.com>
`Cc: QE - Samsung Bioepis <qe-samsungbioepis@quinnemanuel.com>; 'MYL_REG_IPR@rmmslegal.com'
`<MYL_REG_IPR@rmmslegal.com>; 'Lora Green' <lgreen@geminilaw.com>; 'Franklin Chu'
`<fchu@geminilaw.com>; 'rcerwinski@geminilaw.com' <rcerwinski@geminilaw.com>;
`'azalcenstein@geminilaw.com' <azalcenstein@geminilaw.com>; 'bmorris@geminilaw.com'
`<bmorris@geminilaw.com>; Brausa, Adam R. <ABrausa@mofo.com>; Durie, Daralyn J.
`<DDurie@mofo.com>; Davis, Kira A <KiraDavis@mofo.com>; Weires, Rebecca <RWeires@mofo.com>;
`Regeneron-MoFo-IPR <Regeneron-MoFo-IPR@mofo.com>; Wilk, Matthew M.
`<Matthew.Wilk@arnoldporter.com>; Cobb, Jeremy <Jeremy.Cobb@arnoldporter.com>; Caine, David A.
`<David.Caine@arnoldporter.com>
`Subject: RE: IPR2023-00884: Additional Discovery
`
`External Email
`
`4
`
`Samsung Bioepis Exhibit 1070
`Page 4
`
`

`

`Drew,
`
`I don’t think Mylan’s review needs to hold up our discussions. I remain available to talk today or can talk
`before 12:30 pm ET tomorrow.
`
`Regards,
`Laura
`
`From: Hillier, Drew Alan <DHillier@mofo.com>
`Sent: Thursday, May 2, 2024 2:59 PM
`To: Laura Fairneny <laurafairneny@quinnemanuel.com>
`Cc: QE - Samsung Bioepis <qe-samsungbioepis@quinnemanuel.com>; 'MYL_REG_IPR@rmmslegal.com'
`<MYL_REG_IPR@rmmslegal.com>; 'Lora Green' <lgreen@geminilaw.com>; 'Franklin Chu'
`<fchu@geminilaw.com>; 'rcerwinski@geminilaw.com' <rcerwinski@geminilaw.com>;
`'azalcenstein@geminilaw.com' <azalcenstein@geminilaw.com>; 'bmorris@geminilaw.com'
`<bmorris@geminilaw.com>; Brausa, Adam R. <ABrausa@mofo.com>; Durie, Daralyn J.
`<DDurie@mofo.com>; Davis, Kira A <KiraDavis@mofo.com>; Weires, Rebecca <RWeires@mofo.com>;
`Regeneron-MoFo-IPR <Regeneron-MoFo-IPR@mofo.com>; Wilk, Matthew M.
`<Matthew.Wilk@arnoldporter.com>; Cobb, Jeremy <Jeremy.Cobb@arnoldporter.com>; Caine, David A.
`<David.Caine@arnoldporter.com>
`Subject: RE: IPR2023-00884: Additional Discovery
`
`[EXTERNAL EMAIL from dhillier@mofo.com]
`
`Laura,
`
`As Mylan indicated in the attached email, Mylan “need[s] at least another day” before it can confirm
`whether it objects to the production. We also need more time to communicate with Regeneron’s
`district court counsel because this implicates the district court litigation. Let’s plan to discuss on
`Tuesday to make sure all the parties have time to make progress on resolving these issues without
`motion practice. Are you available at 10:00 a.m. PT? If so, we can use this dial-in information:
`
`________________________________________________________________________________
`Microsoft Teams Need help?
`Join the meeting now
`Meeting ID: 242 612 177 303
`Passcode: twwe6f
`
`Dial-in by phone
`+1 628-212-0656,,681972533# United States, San Francisco
`Find a local number
`Phone conference ID: 681 972 533#
`For organizers: Meeting options | Reset dial-in PIN
`________________________________________________________________________________
`
`Best,
`
`Drew
`
`5
`
`Samsung Bioepis Exhibit 1070
`Page 5
`
`

`

`Drew Alan Hillier
`Associate
`DHillier@mofo.com
`T +1 (858) 314-7711
`M +1 (858) 252-5131
`
`<image001.png>
`
`From: Laura Fairneny <laurafairneny@quinnemanuel.com>
`Sent: Thursday, May 2, 2024 11:22 AM
`To: Hillier, Drew Alan <DHillier@mofo.com>
`Cc: QE - Samsung Bioepis <qe-samsungbioepis@quinnemanuel.com>; 'MYL_REG_IPR@rmmslegal.com'
`<MYL_REG_IPR@rmmslegal.com>; 'Lora Green' <lgreen@geminilaw.com>; 'Franklin Chu'
`<fchu@geminilaw.com>; 'rcerwinski@geminilaw.com' <rcerwinski@geminilaw.com>;
`'azalcenstein@geminilaw.com' <azalcenstein@geminilaw.com>; 'bmorris@geminilaw.com'
`<bmorris@geminilaw.com>; Brausa, Adam R. <ABrausa@mofo.com>; Durie, Daralyn J.
`<DDurie@mofo.com>; Davis, Kira A <KiraDavis@mofo.com>; Weires, Rebecca <RWeires@mofo.com>;
`Regeneron-MoFo-IPR <Regeneron-MoFo-IPR@mofo.com>; Wilk, Matthew M.
`<Matthew.Wilk@arnoldporter.com>; Cobb, Jeremy <Jeremy.Cobb@arnoldporter.com>; Caine, David A.
`<David.Caine@arnoldporter.com>
`Subject: RE: IPR2023-00884: Additional Discovery
`
`External Email
`
`Drew,
`
`I disagree with many of your characterizations of the parties’ discussions on this issue. For example, I
`never said SB “wanted discovery about the ‘601 patent,” but said I didn’t understand how Regeneron
`thought it could redact testimony and exhibits it deemed relevant to only the ‘572 patent. Likewise, I’ve
`already explained that your request in bullet three of your email below is not a productive exercise
`conducive to working towards resolution of this issue given the substantial amount of overlap between
`the subject matter of Dr. Yancopoulos’s and Ms. Chu’s testimony here as compared to their testimony in
`the Mylan Litigations based on the publicly available portions we have been able to review.
`
`Given that I have already responded to your other items, let’s meet and confer today at 3:45 p.m. ET.
`
`Regards,
`Laura
`
`From: Hillier, Drew Alan <DHillier@mofo.com>
`Sent: Thursday, May 2, 2024 12:27 PM
`To: Laura Fairneny <laurafairneny@quinnemanuel.com>
`Cc: QE - Samsung Bioepis <qe-samsungbioepis@quinnemanuel.com>; 'MYL_REG_IPR@rmmslegal.com'
`<MYL_REG_IPR@rmmslegal.com>; 'Lora Green' <lgreen@geminilaw.com>; 'Franklin Chu'
`<fchu@geminilaw.com>; 'rcerwinski@geminilaw.com' <rcerwinski@geminilaw.com>;
`'azalcenstein@geminilaw.com' <azalcenstein@geminilaw.com>; 'bmorris@geminilaw.com'
`<bmorris@geminilaw.com>; Brausa, Adam R. <ABrausa@mofo.com>; Durie, Daralyn J.
`6
`
`Samsung Bioepis Exhibit 1070
`Page 6
`
`

`

`<DDurie@mofo.com>; Davis, Kira A <KiraDavis@mofo.com>; Weires, Rebecca <RWeires@mofo.com>;
`Regeneron-MoFo-IPR <Regeneron-MoFo-IPR@mofo.com>; Wilk, Matthew M.
`<Matthew.Wilk@arnoldporter.com>; Cobb, Jeremy <Jeremy.Cobb@arnoldporter.com>; Caine, David A.
`<David.Caine@arnoldporter.com>
`Subject: RE: IPR2023-00884: Additional Discovery
`
`[EXTERNAL EMAIL from dhillier@mofo.com]
`
`Laura,
`
`Although the parties were not able to complete the meet and confer, Regeneron writes to summarize
`today’s call regarding Samsung’s request for additional discovery.
`
`1. Regeneron confirmed that it was providing a higher-resolution printout of the PowerPoint
`presentation previously filed as Ex. 2007and a version of Ex. 2011 without a trial exhibit stamp
`that had obscured some text on the cover page.
`
`1. Regeneron asked if Samsung would agree to limit its request for additional discovery to an
`identifiable subject matter that is tailored to the relevant issues regarding the ’572 patent.
`Samsung stated that it also wanted discovery about the ’601 patent. Although Samsung would
`not agree on the call to limit the requests to certain topics, or even agree to limit the requests to
`the '572 patent, you stated that you would discuss with your team and let us know your
`position.
`
`1. Regeneron asked why Samsung decided to wait approximately two months after the filing of the
`Patent Owner's Response and after the depositions of Dr. Yancopoulos and Ms. Chu to seek this
`discovery. Although Regeneron explained that Samsung’s request for the discovery was
`allegedly “[b]ased on the recent depositions of Karen Chu and George Yancopoulos in this
`proceeding,” Samsung stated that it would not identify any specific testimony. Regeneron
`understands, therefore, that there is nothing in the recent depositions to give rise to this
`request for additional discovery. If that understanding is mistaken, Regeneron asks Samsung for
`the third time to identify the relevant testimony by page and line number so that we can have a
`meaningful meet and confer.
`
`1. We discussed protective order issues. As you know, Mylan’s positions on the protective order in
`the Mylan district court litigation has resulted in motion practice. Out of an abundance of
`caution, we asked if Samsung had confirmed whether Mylan objected to Regeneron producing
`the requested information in light of the district court protective order. Samsung stated that it
`did not know Mylan’s position, although it agreed to ask Mylan. Regeneron also asked whether
`Samsung would be open to a two-tier protective order for these documents. You agreed to
`discuss with your team.
`
`We are available to meet and confer at 12:45 p.m. PT / 3:45 p.m. ET. However, if Samsung is not able to
`provide a written response on the items above by tomorrow at 11:00 a.m. PT, we should wait to speak
`until after you respond so that our call is productive.
`
`Sincerely,
`
`Drew
`
`Drew Alan Hillier
`
`7
`
`Samsung Bioepis Exhibit 1070
`Page 7
`
`

`

`Associate
`DHillier@mofo.com
`T +1 (858) 314-7711
`M +1 (858) 252-5131
`
`<image001.png>
`
`From: Laura Fairneny <laurafairneny@quinnemanuel.com>
`Sent: Wednesday, May 1, 2024 6:13 PM
`To: Hillier, Drew Alan <DHillier@mofo.com>
`Cc: QE - Samsung Bioepis <qe-samsungbioepis@quinnemanuel.com>; 'MYL_REG_IPR@rmmslegal.com'
`<MYL_REG_IPR@rmmslegal.com>; 'Lora Green' <lgreen@geminilaw.com>; 'Franklin Chu'
`<fchu@geminilaw.com>; 'rcerwinski@geminilaw.com' <rcerwinski@geminilaw.com>;
`'azalcenstein@geminilaw.com' <azalcenstein@geminilaw.com>; 'bmorris@geminilaw.com'
`<bmorris@geminilaw.com>; Brausa, Adam R. <ABrausa@mofo.com>; Durie, Daralyn J.
`<DDurie@mofo.com>; Davis, Kira A <KiraDavis@mofo.com>; Weires, Rebecca <RWeires@mofo.com>;
`Regeneron-MoFo-IPR <Regeneron-MoFo-IPR@mofo.com>; Wilk, Matthew M.
`<Matthew.Wilk@arnoldporter.com>; Cobb, Jeremy <Jeremy.Cobb@arnoldporter.com>; Caine, David A.
`<David.Caine@arnoldporter.com>
`Subject: RE: IPR2023-00884: Additional Discovery
`
`External Email
`
`Drew,
`
`I appreciate the meet and confer earlier today and write to respond to the requests you made during
`our discussion.
`
`First, we will confirm with Mylan that it does not object to the requested production. As explained on
`the call, we do not understand why this step is necessary given that the requested materials relate to
`Regeneron’s fact witnesses and documents, but we will nevertheless make this request of Mylan in the
`interest of reaching agreement on these issues.
`
`Second, SB agrees not to seek any additional deposition of Dr. Yancopoulos or Ms. Chu based on the
`production of the additional discovery assuming Regeneron does not submit any further declaration
`from these witnesses.
`
`Third, SB agrees that documents produced on an Outside Counsel’s Eyes Only basis in the Mylan
`Litigation can be designated as Outside Counsel Eye’s Only in this IPR.
`
`Finally, we do not agree to allow Regeneron to redact the requested materials for relevance before
`production. As explained on the call, it’s not clear how Regeneron would be able to determine what is
`relevant versus what is not, and performing the redactions only requires more burden and delay in
`producing the materials.
`
`As discussed on the call, we need to resolve whether the parties can reach an agreement or are at an
`impasse by tomorrow. Please let me know your availability to meet and confer between 11:00 am to
`5:00 pm ET.
`
`8
`
`Samsung Bioepis Exhibit 1070
`Page 8
`
`

`

`Regards,
`Laura
`
`From: Hillier, Drew Alan <DHillier@mofo.com>
`Sent: Tuesday, April 30, 2024 11:12 AM
`To: Laura Fairneny <laurafairneny@quinnemanuel.com>
`Cc: QE - Samsung Bioepis <qe-samsungbioepis@quinnemanuel.com>; 'MYL_REG_IPR@rmmslegal.com'
`<MYL_REG_IPR@rmmslegal.com>; 'Lora Green' <lgreen@geminilaw.com>; 'Franklin Chu'
`<fchu@geminilaw.com>; 'rcerwinski@geminilaw.com' <rcerwinski@geminilaw.com>;
`'azalcenstein@geminilaw.com' <azalcenstein@geminilaw.com>; 'bmorris@geminilaw.com'
`<bmorris@geminilaw.com>; Brausa, Adam R. <ABrausa@mofo.com>; Durie, Daralyn J.
`<DDurie@mofo.com>; Davis, Kira A <KiraDavis@mofo.com>; Weires, Rebecca <RWeires@mofo.com>;
`Regeneron-MoFo-IPR <Regeneron-MoFo-IPR@mofo.com>; Wilk, Matthew M.
`<Matthew.Wilk@arnoldporter.com>; Cobb, Jeremy <Jeremy.Cobb@arnoldporter.com>; Caine, David A.
`<David.Caine@arnoldporter.com>
`Subject: RE: IPR2023-00884: Additional Discovery
`
`[EXTERNAL EMAIL from dhillier@mofo.com]
`
`Laura,
`
`Thank you for the email. Before we have a call, as previously requested, please identify the specific
`transcript testimony that Samsung believes justifies this discovery request and explain the alleged
`relevance of the exhibits. We need this information so that we have a meaningful call. We are available
`May 1 or May 2 at 2:00 p.m. PT.
`
`Samsung was undoubtedly aware of the requested documents before the depositions in this proceeding
`of Dr. Yancopoulos and Ms. Chu. The subject of Dr. Yancopoulos’s and Ms. Chu’s testimony was also
`apparent in their declarations which were filed some time ago. If Samsung wanted to examine whether
`past statements were consistent, Samsung should have asked the witnesses about those statements at
`their depositions. Therefore, it is not clear to us why Samsung waited until after the depositions to
`request these materials.
`
`We will serve a higher-resolution printout of the PowerPoint presentation previously filed as Ex.
`2007and a version of Ex. 2011 without a trial exhibit stamp that had obscured some text on the cover
`page.
`
`Best,
`
`Drew
`
`Drew Alan Hillier
`Associate
`DHillier@mofo.com
`T +1 (858) 314-7711
`M +1 (858) 252-5131
`
`<image001.png>
`
`From: Laura Fairneny <laurafairneny@quinnemanuel.com>
`Sent: Friday, April 26, 2024 2:02 PM
`
`9
`
`Samsung Bioepis Exhibit 1070
`Page 9
`
`

`

`To: Hillier, Drew Alan <DHillier@mofo.com>
`Cc: QE - Samsung Bioepis <qe-samsungbioepis@quinnemanuel.com>; 'MYL_REG_IPR@rmmslegal.com'
`<MYL_REG_IPR@rmmslegal.com>; 'Lora Green' <lgreen@geminilaw.com>; 'Franklin Chu'
`<fchu@geminilaw.com>; 'rcerwinski@geminilaw.com' <rcerwinski@geminilaw.com>;
`'azalcenstein@geminilaw.com' <azalcenstein@geminilaw.com>; 'bmorris@geminilaw.com'
`<bmorris@geminilaw.com>; Brausa, Adam R. <ABrausa@mofo.com>; Durie, Daralyn J.
`<DDurie@mofo.com>; Davis, Kira A <KiraDavis@mofo.com>; Weires, Rebecca <RWeires@mofo.com>;
`Regeneron-MoFo-IPR <Regeneron-MoFo-IPR@mofo.com>; Wilk, Matthew M.
`<Matthew.Wilk@arnoldporter.com>; Cobb, Jeremy <Jeremy.Cobb@arnoldporter.com>; Caine, David A.
`<David.Caine@arnoldporter.com>
`Subject: RE: IPR2023-00884: Additional Discovery
`
`External Email
`
`Drew,
`
`Upon review of the trial transcript in the Mylan Litigation and the available deposition designations at
`that same trial from Ms. Chu, it appears that Dr. Yancopoulos and Ms. Chu provided testimony in the
`Mylan Litigation on subject matter that is substantially similar to their depositions in this IPR. SB should
`be allowed to examine Dr. Yancopoulos’s and Ms. Chu’s prior testimony in the Mylan Litigation for
`consistency with their IPR declarations and testimony. The exhibits cited in that prior testimony are
`necessary for us to fully evaluate and effectively use any statements therein.
`
`As to Exhibits 2007 and 2011, at his deposition, Dr. Yancopoulos testified that there appeared to be
`information missing or obscured in both exhibits. See Yancopoulos Dep. Tr. at 16:13-17:3, 227:23-
`228:10.
`
`We are available to meet and confer on Monday from 2-5pm ET or on Tuesday from 10am-2pm ET.
`
`Regards,
`Laura
`
`From: Hillier, Drew Alan <DHillier@mofo.com>
`Sent: Thursday, April 25, 2024 5:01 PM
`To: Laura Fairneny <laurafairneny@quinnemanuel.com>
`Cc: QE - Samsung Bioepis <qe-samsungbioepis@quinnemanuel.com>; 'MYL_REG_IPR@rmmslegal.com'
`<MYL_REG_IPR@rmmslegal.com>; 'Lora Green' <lgreen@geminilaw.com>; 'Franklin Chu'
`<fchu@geminilaw.com>; 'rcerwinski@geminilaw.com' <rcerwinski@geminilaw.com>;
`'azalcenstein@geminilaw.com' <azalcenstein@geminilaw.com>; 'bmorris@geminilaw.com'
`<bmorris@geminilaw.com>; Brausa, Adam R. <ABrausa@mofo.com>; Durie, Daralyn J.
`<DDurie@mofo.com>; Davis, Kira A <KiraDavis@mofo.com>; Weires, Rebecca <RWeires@mofo.com>;
`Regeneron-MoFo-IPR <Regeneron-MoFo-IPR@mofo.com>; Wilk, Matthew M.
`<Matthew.Wilk@arnoldporter.com>; Cobb, Jeremy <Jeremy.Cobb@arnoldporter.com>; Caine, David A.
`<David.Caine@arnoldporter.com>
`Subject: RE: IPR2023-00884: Additional Discovery
`
`[EXTERNAL EMAIL from dhillier@mofo.com]
`
`10
`
`Samsung Bioepis Exhibit 1070
`Page 10
`
`

`

`Laura,
`
`We are looking into providing higher-resolution copies of Exhibits 2007 and 2011, although we are not
`aware of any “missing” information.
`
`Regarding “the collaboration agreement between Bayer and Regeneron,” we believe copies are equally
`available to Samsung at SEC.gov.
`
`Regeneron would like to meet and confer to understand the remainder of Samsung’s request. Before
`we schedule a call, please identify the specific testimony in the depositions of Karen Chu and George
`Yancopoulos on which Samsung is relying to attempt to justify the additional discovery. For each
`requested exhibit, please explain the alleged relevance so that we can have a meaningful meet and
`confer.
`
`Sincerely,
`
`Drew
`
`Drew Alan Hillier
`Associate
`DHillier@mofo.com
`T +1 (858) 314-7711
`M +1 (858) 252-5131
`
`<image001.png>
`
`From: Laura Fairneny <laurafairneny@quinnemanuel.com>
`Sent: Tuesday, April 16, 2024 1:41 PM
`To: Brausa, Adam R. <ABrausa@mofo.com>; Durie, Daralyn J. <DDurie@mofo.com>; Davis, Kira A
`<KiraDavis@mofo.com>; Weires, Rebecca <RWeires@mofo.com>; Regeneron-MoFo-IPR <Regeneron-
`MoFo-IPR@mofo.com>; Wilk, Matthew M. <Matthew.Wilk@arnoldporter.com>; Cobb, Jeremy
`<Jeremy.Cobb@arnoldporter.com>; Caine, David A. <David.Caine@arnoldporter.com>
`Cc: QE - Samsung Bioepis <qe-samsungbioepis@quinnemanuel.com>; 'MYL_REG_IPR@rmmslegal.com'
`<MYL_REG_IPR@rmmslegal.com>; 'Lora Green' <lgreen@geminilaw.com>; 'Franklin Chu'
`<fchu@geminilaw.com>; 'rcerwinski@geminilaw.com' <rcerwinski@geminilaw.com>;
`'azalcenstein@geminilaw.com' <azalcenstein@geminilaw.com>; 'bmorris@geminilaw.com'
`<bmorris@geminilaw.com>
`Subject: IPR2023-00884: Additional Discovery
`
`External Email
`
`Counsel,
`
`11
`
`Samsung Bioepis Exhibit 1070
`Page 11
`
`

`

`Based on the recent depositions of Karen Chu and George Yancopoulos in this proceeding,
`Petitioner requests the following limited additional discovery pursuant to 37 C.F.R. §
`42.51(b)(2):
`
`1. The deposition transcript of Karen Chu from Regeneron Pharmaceuticals, Inc. v. Mylan
`Pharmaceuticals, Inc., Case No. 22-cv-61-TSK (N.D.W. Va.) (“Mylan Litigation”) and
`all exhibits thereto;
`2. The deposition transcript of George Yancopoulos from the Mylan Litigation and all
`exhibits thereto;
`3. The trial exhibits from the Mylan Litigation cited in the trial testimony of Karen Chu
`and/or George Yancopoulos, including: PTX 0001, PTX 0003, PTX 0080, PTX 0188,
`PTX 0304, PTX 0311, PTX 0491, PTX 0686, PTX 0932, PTX 1028C, PTX 1170, PTX
`3131, PTX 3133, PTX 3150, PTX 3151, PTX 3167, PTX 3168, PTX 3187, PTX 3188,
`PTX 3216, PTX 3332, PTX 3333, PDX 1-1, PDX 1-2, PDX 3.001, PDX 3.002, PDX
`3.004, PDX 3-0311-B, PDX 932-C, DTX 0019, DTX 0212, DTX 0216, DTX 0227, DTX
`0228, DTX 0902, DTX 0913, DTX 0915, DTX 0916, DTX 2053, DTX 2053A, DTX
`2730, DTX 2745, DTX 3196, DTX 4070, DTX 4957, DTX 5073, DTX 5082, DTX 5385,
`DTX 7001, DTX 7212, DTX 7272, DTX 8127, DTX 8180, DTX 8190, DTX 9002, DTX
`9003, DTX 9005, DTX 9006;
`4. The following trial exhibits from the Mylan Litigation cited in the Court’s Memorandum
`Opinion and Order Following Bench Trial (ECF No. 692 in the Mylan Litigation): DTX
`0213, DTX 0220, DTX 0222, DTX 0226, DTX 0229, DTX 0230, DTX 0232, DTX 0234;
`5. The collaboration agreement between Bayer and Regeneron, and any amendments
`thereto; and
`6. Corrected copies of Exs. 2007 and 2011 that includes missing text and figures (see, e.g.,
`Ex. 2007 at pp. 39, 48 and Ex. 2011 at p. 1).
`
`Please let us know if Patent Owner agrees to make this limited production of requested
`documents.
`
`Regards,
`
`Laura Fairneny
`Partner
`quinn emanuel urquhart & sullivan, llp
`
`51 Madison Avenue, 22nd Floor
`New York, NY 10010
`212.849.7333 Direct
`212.849.7000 Main Office Number
`212.849.7100 FAX
`laurafairneny@quinnemanuel.com
`www.quinnemanuel.com
`
`NOTICE: The information contained in this e-mail message is intended only for the personal and confidential use of the recipient(s) named
`above. This message may be an attorney-client communication and/or work product and as such is privileged and confidential. If the reader
`of this message is not the intended recipient or agent responsible for delivering it to the intended recipient, you are hereby notified that you
`have received this document in error and that any review, dissemination, distribution, or copying of this message is strictly prohibited. If you
`have received this communication in error, please notify us immediately by e-mail, and delete the original message.
`
`12
`
`Samsung Bioepis Exhibit 1070
`Page 12
`
`

`

`=====================================================================
`=======
`
`This message may be confidential and privileged. Use or disclosure by anyone other than an intended
`addressee is prohibited. If you received this message in error, please delete it and advise the sender by
`reply email. Learn about Morrison & Foerster LLP's Privacy Policy.
`
`====================================================================
`=======
`
`. =
`
`This message may be confidential and privileged. Use or disclosure by anyone other than an intended
`addressee is prohibited. If you received this message in error, please delete it and advise the sender by
`reply email. Learn about Morrison & Foerster LLP's Privacy Policy.
`
`====================================================================
`=======
`
`This message may be confidential and privileged. Use or disclosure by anyone other than an intended
`addressee is prohibited. If you received this message in error, please delete it and advise the sender by
`reply email. Learn about Morrison & Foerster LLP's Privacy Policy.
`
`====================================================================
`=======
`
`. =
`
`. =
`
`This message may be confidential and privileged. Use or disclosure by anyone other than an intended
`addressee is prohibited. If you received this message in error, please delete it and advise the sender by
`reply email. Learn about Morrison & Foerster LLP's Privacy Policy.
`
`. =
`
`===========================================================================
`
`This message may be confidential and privileged. Use or disclosure by anyone other than an intended
`addressee is prohibited. If you received this message in error, please delete it and advise the sender by
`reply email. Learn about Morrison & Foerster LLP's Privacy Policy.
`.
`
`============================================================================
`
`This message may be confidential and privileged. Use or disclosure by anyone other than an intended addressee is
`prohibited. If you received this message in error, please delete it and advise the sender by reply email. Learn about
`
`13
`
`Samsung Bioepis Exhibit 1070
`Page 13
`
`

`

`Morrison & Foerster LLP's Privacy Policy.
`
`. =
`
`===========================================================================
`
`This message may be confidential and privileged. Use or disclosure by anyone other than an intended addressee is
`prohibited. If you received this message in error, please delete it and advise the sender by reply email. Learn about
`Morrison & Foerster LLP's Privacy Policy.
`.
`
`14
`
`Samsung Bioepis Exhibit 1070
`Page 14
`
`